AKI Clinical Trial
Official title:
Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial
NCT number | NCT05036616 |
Other study ID # | IRB.151/64 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2021 |
Est. completion date | December 31, 2023 |
This investigation aims to evaluate the filter life time of CRRT membrane and complication of combining ECMO and CRRT.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. > 18 years 2. Refractory acidosis (pH<7.2 or HCO3<15) 3. Refractory volume overload 4. Refractory hyperkalemia (K>6.2mEq/L or EKG change) 5. Anuria or oliguria (urine output <0.5 mL/kg/hr for 6-12hr) 6. High BUN >100 mg/dL or uremic symptom 7. Increase intracranial pressure Exclusion Criteria: 1. Pregnancy 2. Not use heparin in ECMO 3. Chronic kidney disease with CRRT 4. AKI with Glomerulonephritis, Interstitial nephritis, Vassculitis or Urinary tract obstruction |
Country | Name | City | State |
---|---|---|---|
Thailand | Sasipha tachaboon | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Chulalongkorn University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Circuit lifetime | The time until a CVVH malfunction was identified | 72 hours | |
Secondary | Cost-Effectiveness | To evaluate the cost utility of CRRT between 2 groups | 72 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04112953 -
Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
|
||
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Active, not recruiting |
NCT04008810 -
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
|
||
Recruiting |
NCT04597034 -
Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19
|
N/A | |
Completed |
NCT04458571 -
Effect of CRRT Duration on Solute Removal
|
||
Recruiting |
NCT04114747 -
Renal Physiology During Continuous Renal Replacement Therapy
|
N/A | |
Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
Not yet recruiting |
NCT05382078 -
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
|
||
Recruiting |
NCT04351906 -
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
Completed |
NCT04762524 -
The Impact of CRRT Modality on Filter Life
|
N/A | |
Completed |
NCT04048525 -
Cytokine Removal With CVVHD Compared to CVVH
|
N/A | |
Completed |
NCT04788394 -
Renal Involvement in Hospitalized Children With COVID-19
|
||
Recruiting |
NCT04474249 -
Follow-up of Critical COVID-19 Patients
|
||
Completed |
NCT04517630 -
Renal Biomarkers in AKI and COVID-19
|
||
Completed |
NCT04407156 -
Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom
|
||
Recruiting |
NCT04895384 -
El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)
|
||
Completed |
NCT03070353 -
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
|
Phase 2/Phase 3 |